Clinical Trials Browser

INDUSTRY × Lymphoma, B-Cell × ublituximab × Clear all

Recurrence, Lymphoma, B-Cell

NCT01647971 2022-11-21

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT03778073 2022-08-22

Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

Phase 1 Terminated

18 enrolled

Lymphoid

Recurrence, Lymphoma, B-Cell

NCT01744912 2022-05-11

Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies

Phase 1 Terminated

10 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Clinical Trials

Study of TG-1801 in Subjects With B-Cell Lymphoma

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies